Oracle's 2052 bonds are offering a rare 7% yield. Read about the risks and if they're right for income-focused investors.
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback